Analysis of 20 patients with laparoscopic extended right colectomy

Table 1 Patient demographics and pathological characteristics

Variable	n (%)
Age, median (range)	63.5 (26–75)
Sex (male)	15 (75)
BMI (> 25)	7 (35)
ASA ≤ 2	19 (95)
Tumor location
Hepatic flexure	13 (65)
Right transverse	7 (35)
Pathology
pT1	0 (0)
pT2	1 (5)
pT3	16 (80)
pT4	3 (15)
pN0	9 (45)
pN1	7 (35)
pN2	4 (20)
Perineural invasion	5 (25)
Vascular invasion	8 (40)
Defective mismatch repair	5 (25)
Intraoperative complications	0 (0)
Transition to open abdomen	0 (0)

CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiologists.

Table 2 Peri- and postoperative patient outcomes

Variable	n (%)
Postoperative complication	5 (25)
Anastomotic leakage	0 (0)
Pancreatic fistula POPF grade
Grade A	0 (0)
Grade B	1 (5)
Grade C	0 (0)
Intestinal obstruction	2 (10)
Chylous ascites	1 (5)
Incision infection	1 (5)
Gastroparesis	2 (10)
Organ infection	0 (0)
Gastrointestinal bleeding	1 (5)
Clavien–Dindo classification
Grade I	1 (5)
Grade II	5 (25)
Grade III and above	1 (5)
Anal exhaust time, median (range) (d)	3 (2-6)
Semiliquid diet, median (range) (d)	5 (4-7)
Length of hospital stay	11.5 (8-24)

POPF: Postoperative pancreatic fistula.

Table 3 Lymph node yield and metastases

Variable	n (%)
Total LN yield, mean ± SD	39.3 ± 10.9
LN metastases, median (range)	1 (0-28)
No. 204 LN yield, median (range)	2 (0-8)
No. 206 LN yield, median (range)	2.5 (0-9)
Apical LN metastases	8 (40)
No. 204 LN metastases	1 (5)
No. 206 LN metastases	1 (5)

LN: Lymph node.

Table 4 Characteristics of the patients with gastrocolic ligament lymph node metastasis

Patient	Patient 1	Patient 2
Age (yr)	69	61
Gender	Female	Female
BMI	30.04	20.96
Symptom	Abdominal pain	Abdominal pain
CEA (ng/mL)	33.28	25.39
ASA score	II	III
Location	R	H
Pathological type	Ulcerative	Ulcerative
Differentiation	M	m-p
T stage	T4a	T3
N stage	N2	N2
Tumor size (cm)	6.0 × 3.5	6.0 × 5.5
Mesocolic LN metastases/mesocolic LN yield (n)	5/34	28/58
Apical LN metastases/apical LN yield (n)	4/13	16/30
No. 204 LN metastases/GCLN yield (n)	1/2	0/2
No. 206 LN metastases/GCLN yield (n)	0/6	3/3
Venous invasion (n)	Yes	Yes
Perineural invasion (n)	No	Yes
Mismatch repair protein	Expression	Expression
Postoperative complications	No	No
Chemotherapy method	XELOX	XELOX
Relapse	No	Metastasis
Mortality	Alive	Death

CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiologists; CEA: Carcinoembryonic antigen; ASA: American Society of Anesthesiologists; GCLN: Gastrocolic ligament lymph node; R: Right transverse; T: Hepatic flexure; m-p: moderately differentiated-poorly differentiated; XELOX: Oxaliplatin combined with capecitabine.